gastric cancer
trial update
The last patient has been enrolled in a phase 2 pilot trial evaluating the safety and efficacy of Tumor Treating Fields in combination with chemotherapy as a first-line treatment in gastric adenocarcinoma.
learn more
clinical trial
collaboration
We entered into a clinical trial collaboration agreement with Roche to evaluate Tumor Treating Fields as part of a novel combination for the first-line treatment of metastatic pancreatic cancer.
learn more
breakthrough
device designation
The FDA granted breakthrough designation to the NovoTTF-200T System™ intended for use together with atezolizumab and bevacizumab for the first-line treatment of patients with unresectable or metastatic liver cancer.
learn more
top workplace
in New Hampshire
We’ve been recognized as a top employer in New Hampshire, where our U.S. Operations Center is based. Learn more about what makes working at Novocure special.
learn more
the story
of Novocure
We are a global oncology company striving to extend survival in some of the most aggressive forms of cancer. In 2000, our founder Professor Yoram Palti sought to leverage his expertise in biophysics to develop a new way to treat cancer that would destroy tumor cells while sparing healthy tissue and avoiding many of the life-altering side effects of existing cancer therapies. Novocure has grown into an international oncology company with more than 1,000 employees and operations in the U.S., Europe and Asia. With more than 20 years of research and many significant milestones, we believe we are only beginning.
Learn More
we can leverage physics to fight cancer
Tumor Treating Fields is a cancer therapy that uses electric fields to disrupt cancer cell division.
OUR THERAPY
explore our clinical pipeline
Our research shows that Tumor Treating Fields have an antimitotic effect in more than 18 solid tumor types in culture and in eight in vivo tumor models.
OUR PIPELINE
we are dedicated to making a difference in cancer
Patients remain at the heart of the work we do every day. Learn more about our patients, their families and the people working to deliver patient-forward therapies to treat cancer.
PATIENT-FORWARD